COOPERATION AGREEMENT

Exhibit 10.1

COOPERATION AGREEMENT

March 8, 2022

Xxxxxx Executive Capital LP
c/o Cadwalader, Xxxxxxxxxx & Xxxx LLP
000 Xxxxxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000

Ladies and Gentlemen:

ViewRay, Inc. (the “Company”) and Xxxxxx Executive Capital LP, on behalf of itself, its affiliates and its affiliated funds (such affiliates and affiliated funds (which, for the avoidance of doubt, shall include HEC Management GP LLC and HEC Master Fund LP), together with Xxxxxx Executive Capital LP, collectively, “Xxxxxx”), have agreed to the terms contained in this Cooperation Agreement (this “Agreement”). This Agreement will take effect as of the date hereof (the “Effective Date”). For purposes of this Agreement, we refer to each of the Company and Xxxxxx as a “Party” and, together, as the “Parties”.

1.Company Board and Related Matters.

(a)Board Actions. As of the date of this Agreement, the Board of Directors of the Company (the “Board”) has taken the following actions:

(i)the Board has duly appointed Xxxxx Xxxxxxxx to fill the vacant seat (the “Director”) on the Board to serve as a Class II director, which individual is independent of each of the Company and Xxxxxx and will serve a term expiring at the Company’s 2023 annual meeting of shareholders (including any adjournments or postponements thereof, the “2023 Annual Meeting”); and

(ii)the Board has determined the Director’s “independence” under the rules and regulations of the Nasdaq Stock Market (“Nasdaq”), the U.S. Securities and Exchange Commission (“SEC”) rules and regulations and the guidelines of the Company’s independent registered public accounting firm and in accordance with its customary and generally applicable procedures for evaluating director candidates.

(b)Shareholder Meetings.

(i)Meetings. At any annual or special meeting of shareholders of the Company during the Term (including any action of the shareholders by written consent), Xxxxxx shall, or shall cause its Affiliates, Associates (each as defined in Rule 12b-2 promulgated by the SEC under the Exchange Act of 1934, as amended (together with the rules and regulations thereunder, the “Exchange Act”) or representatives to, appear in person or by proxy at such meeting (or submit written consents) and vote all shares of Common Stock over which Xxxxxx, its Affiliates or Associates has voting power (A) in favor of all directors nominated by the Board for election at any such meeting, (B) in accordance with the Board’s recommendation with respect to any proposal to be submitted to the shareholders of the Company; provided, however, that Xxxxxx shall be permitted to vote in its discretion on any proposal of the Company in respect of any Extraordinary Transaction (as defined below).

(ii)Interim Special Meetings. During the Term, the Company shall not call or hold any interim special meeting of shareholders for the purpose of removing and/or replacing the Director.

(c)Board Size. During the Term, the size of the Board will not be more than nine (9) directors; provided, that the size of the Board may be increased to ten (10) directors in connection with the appointment of Xxx Xxxxxxx to the Board.

(d)Company Policies. The policies, procedures, processes, codes, rules, standards and guidelines applicable to other directors of the Company, including the Corporate Governance Guidelines and Code of Business Conduct and Ethics, and any other policies applicable to members of the Board, including, but not limited to, policies related to stock ownership, public disclosures and confidentiality (as may be amended from time to time, collectively, the “Company Policies”) will be applicable to the Director during such director’s term of service. The Company represents and warrants that all Company Policies currently in effect are publicly available on the Company’s website or have been provided to Xxxxxx or its counsel. For the avoidance of doubt, the Company Policies shall not apply to Xxxxxx or any of their affiliated funds.

(e)Non-Interference. The Company will not take any action to frustrate the purposes of this Agreement, including by (i) amending or making any alterations to its organizational documents or any Company Policies or (ii) utilizing any existing or new committee of the Board.

(f)Committees. As of the Effective Date, the Board has duly appointed the Director to serve on the Finance Committee of the Board. The Director or any Successor Director that replaces the Director on the Board shall continue to serve on such committee for so long as he or she is serving as a member of the Board as an independent director and otherwise continues to satisfy the eligibility requirements of such committee that are in place as of the execution of this Agreement, unless otherwise agreed by Xxxxxx in writing. The Director will have the same access to all Board committee materials and meetings as all the other members of the Board. The Company shall not form any new committee of the Board unless the Director or the Xxxxxx Consultant (as defined below), if he is then serving on the Board, is a member of such committee. The appointment and service of the Director and any successors on the foregoing committee shall be subject to their continued qualifications to serve on such committee under the Nasdaq Listing Rules, the applicable SEC rules and regulations and the guidelines of the Company’s independent registered public accounting firm.

(g)Successor Director.

(i)If the Director ceases to serve as a member of the Board prior to the Expiration Date, Xxxxxx shall be entitled to select another individual to be appointed to the Board (a “Successor Director”) following the same process under which Xxxxxx suggested, and the Company vetted, from a pool of candidates to mutually identify the Director. The Successor Director shall be independent of each of the Company and Xxxxxx, shall qualify as “independent” under the Nasdaq Listing Rules, the SEC rules and regulations and the guidelines of the Company’s independent registered public accounting firm, and have qualifications, experience and industry expertise that are substantially similar to the Director (or any Successor Director) being replaced. The Company shall take all necessary actions to promptly appoint such Successor Director to the Board as a Class II director and the applicable committee(s), subject to the approval (not to be unreasonably withheld) of the Nominating and Corporate Governance Committee of the Board, after conducting a good faith and customary process consistent with the Board’s fiduciary duties (and who satisfies the Company Policies applicable to all directors). All references to the “Director,” for purposes of this Agreement, shall be deemed references to the Successor Director that replaced the Director in the event that a Successor Director is appointed.

2

(ii)If the Successor Director proposed by Xxxxxx is rejected for the permitted reasons described in this Section 1(g), Xxxxxx shall be entitled to continue proposing persons as replacement successors to the Board and any such replacement successor shall be promptly appointed to the Board (subject to the Board’s right to reject such person’s candidacy as Successor Director for the permitted reasons described in this Section 1(g)). The onboarding of the Successor Director will be through a reasonable and customary process no more onerous, burdensome or time consuming than the process for onboarding any other director to the Board, and there will be no procedure, policy or other obstacle implemented with the intent or effect of prejudicing the Successor Director’s ability to timely join the Board. The Company shall exercise reasonable best efforts, in cooperation with Xxxxxx, to ensure that any Successor Director is found independent by the relevant regulatory entities.

(iii)Notwithstanding any of the foregoing, Xxxxxx shall not take any action, direct or indirect, to cause the Director to cease serving as a director, and the rights with respect to the designation of a Successor Director described herein shall be subject to Xxxxxx having aggregate beneficial ownership of at least three percent (3%) of the shares of the common stock of the Company, par value $0.01 per share (“Common Stock”), outstanding at such time; provided, that for purposes of such calculation, the total outstanding shares of Common Stock as of the date of such determination shall be deemed to be the lesser of (1) the aggregate number of shares of Common Stock outstanding as of the date hereof or (2) the aggregate number of shares of Common Stock outstanding as of the date of such determination (in each case, as equitably adjusted for any combinations, splits, recapitalizations or similar actions).

(h)Xxxxxx Consultant.

(i)Concurrently with the execution and delivery of this Agreement, the Company shall enter into a consulting agreement (the “Consulting Agreement”) with Xxx Xxxxxxx (the “Xxxxxx Consultant”), pursuant to which, on the terms and subject to the conditions set forth therein, the Xxxxxx Consultant will advise and consult the Company and the Board on public market advice, capital market transactions, and capital allocation.

(ii)Concurrently with the execution and delivery of this Agreement, Xxxxxx and the Xxxxxx Consultant shall deliver to the Company a customary confidentiality agreement in a form to be mutually agreed between the Parties. For the avoidance of doubt, the Parties agree that such confidentiality agreement shall in no event restrict or limit the ability of Xxxxxx to engage in a proxy contest.

(iii)The Board shall, in good faith, consider the Xxxxxx Consultant as a candidate for election to the Board at the 2023 Annual Meeting and to fill any vacancy arising during the Term, subject to the customary vetting processes, including interviews and other onboarding and compliance procedures, of the Nominating and Corporate Governance Committee of the Board.

2.Standstill Restrictions. During the Term, Xxxxxx shall not, and shall cause its controlling and controlled Affiliates and Associates not to, directly or indirectly, in any manner:

(a)purchase or otherwise acquire, or offer, seek, propose or agree to acquire, beneficial ownership of Common Stock such that, giving effect to such purchase or acquisition, Xxxxxx’x beneficial ownership of Common Stock would exceed 14.9% of the Common Stock outstanding;

3

(b)engage in, or assist in the engagement in, soliciting proxies or written consents of shareholders with respect to, or from the holders of, any shares of Common Stock or any other securities of the Company entitled to vote in the election of directors, or securities convertible into, or exercisable or exchangeable for, such shares or other securities, whether or not subject to the passage of time or other contingencies (collectively, “Voting Securities”), or make, or in any way participate in (other than by voting its shares of Voting Securities in a way that does not violate this Agreement), any solicitation of any proxy, consent or other authority to vote any Voting Securities with respect to the election of directors or any other matter, otherwise conduct or assist in the conducting of any binding or nonbinding referendum with respect to the Company, or seek to advise or encourage any person in, any proxy contest or any solicitation with respect to the Company not approved and recommended by the Board, including relating to the removal or the election of directors, other than solicitations or actions as a participant in support of all of the Company’s nominees;

(c)form, join or in any other way participate in a “partnership, limited partnership, syndicate or other group” within the meaning of Section 13(d)(3) of the Exchange Act with respect to any Voting Securities, or deposit any Voting Securities in a voting trust or subject any Voting Securities to any voting agreement or other arrangement of similar effect (other than any such voting trust, arrangement or agreement solely among Xxxxxx and its Affiliates that is otherwise in accordance with this Agreement);

(d)publicly seek to call, or request the call of, a special meeting of the shareholders of the Company or publicly seek to make, or make, a shareholder proposal at any annual or special meeting of the shareholders of the Company, or otherwise become a “participant” in a “solicitation” (as such terms are defined in Instruction 3 of Item 4 of Schedule 14A and Rule 14a-1 of Regulation 14A, respectively, under the Exchange Act) to vote any securities of the Company (including by initiating, encouraging or participating in a “withhold” or similar campaign);

(e)(i) except as expressly permitted by this Agreement, seek, alone or in concert with others, election or appointment to, or representation on, the Board or nominate or propose the nomination of, or recommend the nomination of, any candidate to the Board or (ii) seek, alone or in concert with others, the removal of any member of the Board;

(f)make any request or submit any proposal to amend or waive any of the terms of this Agreement, in each case which would reasonably be expected to result in a public announcement or public disclosure of such request or proposal or give rise to a requirement to so publicly announce or disclose such request or proposal;

(g)advise, encourage, support or influence any person or entity with respect to the voting of (or execution of a written consent in respect of) or disposition of any securities of the Company;

(h)sell or agree to sell, directly or indirectly, through swap or hedging transactions or otherwise, any shares of Common Stock or any derivatives relating to Common Stock to any third party (a “Third Party”) other than a Third Party that (x) is (i) a Party to this Agreement, (ii) a member of the Board or (iii) an officer of the Company or (y) would not, together with its Affiliates, own, control or otherwise have beneficial ownership representing in the aggregate in excess of 4.9% of the shares of Common Stock outstanding at such time as a result of such transfer, except for Schedule 13G filers that are mutual funds, pension funds, index funds or investment fund

4

managers that have not been identified on the most recent “SharkWatch 50” list, as published by FactSet and any successor (the “SharkWatch List”) and are not publicly disclosed Affiliate funds of such a filer on the SharkWatch List; provided, that nothing herein shall restrict or limit Xxxxxx’x ability to sell or otherwise dispose of any shares of Common Stock or any derivatives relating to Common Stock in open market transactions where the identity of the purchaser is not readily available;

(i)take any action in support of or make any proposal, announcement, statement, offer or request, or affirmatively solicit or publicly encourage a third party to make any proposal, announcement, statement, offer or request, regarding: (A) advising, controlling, changing or influencing the Board or management of the Company, including but not limited to, plans or proposals to change the number or term of directors or to fill any vacancies on the Board, (B) any Extraordinary Transaction or exploration thereof (it being understood that this clause 5(i)(B) shall not restrict Xxxxxx from tendering shares, receiving payment for shares or otherwise participating in any such transaction on the same basis as other shareholders of the Company, or from participating in any such transaction that has been approved by the Board) or (C) any other material change in the Company’s or any of its subsidiaries’ operations, business, corporate strategy, corporate structure, capital structure or allocation, or share repurchase or dividend policies; provided, for the avoidance of doubt, that Xxxxxx and its Affiliates shall be entitled to engage in private discussions with respect to such matters with limited partners or shareholders of Xxxxxx or its Affiliates;

(j)engage in any short sale or any purchase, sale or grant of any option, warrant, convertible security, stock appreciation right or other similar right (including any put or call option or “swap” transaction) with respect to any security (other than in connection with a broad-based market basket or index) that relates to or derives any part of its value from any decline in the market price or value of any securities of the Company, and would result in Xxxxxx (together with its affiliates) failing to have an aggregate net long position (as defined in Rule 14e-4 under the Exchange Act) in the Company;

(k)communicate with the Company’s shareholders or others pursuant to Rule 14a-1(l)(2)(iv) under the Exchange Act;

(l)engage in any course of conduct with the purpose of causing shareholders of the Company to vote contrary to the recommendation of the Board on any matter presented to the Company’s shareholders for their vote at any meeting of the Company’s shareholders or by written consent;

(m)publicly act, including by making public announcements or speaking to reporters or members of the media (whether “on the record” or on “background” or “off the record”), to seek to influence the Company’s shareholders, management or the Board with respect to the Company’s policies, operations, balance sheet, capital allocation, marketing approach, business configuration, Extraordinary Transactions, or strategy or to obtain representation on the Board or seek the removal of any director in any manner, except as expressly permitted by this Agreement;

(n)call or seek to call, or request the call of, alone or in concert with others, any meeting of shareholders, whether or not such a meeting is permitted by the Amended and Restated Bylaws (the “Bylaws”), including a “town hall meeting”;

(o)seek, or encourage or advise any person, to submit nominations in furtherance of a “contested solicitation” for the election or removal of directors with

5

respect to the Company or seek, encourage or take any other action with respect to the election, removal or replacement of any directors;

(p)demand a copy of the Company’s list of shareholders or its other books and records or make any request pursuant to Rule 14a-7 under the Exchange Act or under any statutory or regulatory provisions of Delaware providing for stockholder access to books and records (including lists of shareholders) of the Company;

(q)make any request or submit any proposal to amend or waive the terms of this Agreement other than through non-public communications with the Company that would not be reasonably likely to trigger public disclosure obligations for any Party;

(r)disclose in a manner that could reasonably be expected to become public any intent, purpose, plan or proposal with respect to any director or the Company’s management, policies, strategy, operations, financial results or affairs, any of its securities or assets or this Agreement that is inconsistent with the provisions of this Agreement; or

(s)enter into any discussions, negotiations, agreements or understandings with any person with respect to the foregoing, or advise, assist, knowingly encourage or seek to persuade any person to take any action or make any statement with respect to any such action, or otherwise take or cause any action or make any statement inconsistent with any of the foregoing.

The restrictions set forth in this Section 2 shall not apply to the Director acting in her capacity as a director of the Company. The Parties further agree that neither Xxxxxx nor any of its Affiliates shall seek to do indirectly through the Director (or any Successor Directors) anything that would be prohibited if done by Xxxxxx or its Affiliates. For the avoidance of doubt, the Parties acknowledge and agree that Xxxxxx intends to continue to engage in non-public discussions with members of management of the Company and the Board and nothing in this Section 2 shall be deemed to prevent or impede such discussions from occurring, so long as such discussion is not intended to, and would not reasonably be expected to, require any public disclosure of such discussion. The Company shall notify Xxxxxx in writing upon the occurrence of the Expiration Date.

As used herein, “Extraordinary Transaction” means any merger, acquisition, amalgamation, tender offer, exchange offer, recapitalization, restructuring, disposition, distribution, spin-off, asset sale, joint venture or other business combination involving the Company or any of its subsidiaries or that relates to or would result in a Change of Control.

3.Press Release; Form 8-K; Publicity.

(a)The Parties agree that promptly following the execution and delivery of this Agreement by the Parties, (A) the Company will issue the press release attached to this Agreement as Exhibit A (the “Press Release”) and file a Current Report on Form 8-K in the form previously agreed by the Parties and (B) Xxxxxx will file an amendment to its Schedule 13D in the form previously agreed by the Parties.

(b)During the Term, the Company, on the one hand, and Xxxxxx, on the other hand, shall each refrain from making, and shall cause their respective Affiliates and Associates and its and their respective principals, directors, members, general partners, officers, employees, agents and representatives (including, with respect to Xxxxxx, the Xxxxxx Consultant) (collectively, “Representatives”) not to make, any public statement that constitutes an ad hominem attack on, or that otherwise disparages, impugns or is reasonably likely to

6

damage the reputation of, (i) in the case of statements by Xxxxxx or any of its Representatives, the Company or any of its Affiliates or any of its or their respective officers, directors or employees or any person who has served in any of the foregoing capacities, or (ii) in the case of statements by the Company or any of its Representatives, Xxxxxx or any of its Affiliates or any of its or their respective partners, members, officers, directors or employees or any person who has served in the foregoing capacity. The foregoing sentence shall not restrict the ability of any Party to (1) comply with any subpoena or other legal process or respond to a request for information from any governmental authority with jurisdiction over the Party from whom information is sought or (2) make private statements to directors of the Board, employees of the Company, Xxxxxx or employees of Xxxxxx in a manner in which public dissemination of such statements would not be reasonably anticipated.

4.Representations of the Company. The Company represents and warrants to Xxxxxx that (a) the Company has the corporate power and authority to execute and deliver this Agreement and to bind it hereto, (b) this Agreement has been duly and validly authorized, executed and delivered by the Company, constitutes a valid and binding obligation and agreement of the Company, and is enforceable against the Company in accordance with its terms (subject to applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer and other similar laws affecting creditors’ rights generally and to general principles of equity, regardless of whether considered in a proceeding in equity or at law) and (c) the execution, delivery and performance of this Agreement by the Company does not and will not violate or conflict with (i) any law, rule, regulation, order, judgment or decree applicable to the Company, or (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could constitute such a breach, violation or default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding or arrangement to which the Company is a party or by which it is bound.

5.Representations of Xxxxxx. Xxxxxx represents and warrants to the Company that (a) Xxxxxx has the power and authority to execute and deliver this Agreement and to bind itself and its affiliates to this Agreement (and Xxxxxx Executive Capital LP has the power and authority to execute and deliver this Agreement and to bind itself and the entities listed on Schedule A to this Agreement), (b) this Agreement has been duly authorized, executed and delivered by Xxxxxx, constitutes a valid and binding obligation of Xxxxxx, and is enforceable against Xxxxxx in accordance with its terms (subject to applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer and other similar laws affecting creditors’ rights generally and to general principles of equity, regardless of whether considered in a proceeding in equity or at law), (c) the execution of this Agreement by Xxxxxx does not and will not violate or conflict with (i) any law, rule, regulation, order, judgment or decree applicable to Xxxxxx, or (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could constitute such a breach, violation or default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding or arrangement to which Xxxxxx is a party or by which it is bound, (d) Xxxxxx, together with its Affiliates, beneficially owns (as defined in Rule 13d-3 promulgated by the SEC under the Exchange Act) in the aggregate 15,752,093 shares of Common Stock, (e) Xxxxxx is not a party to any swap or hedging transactions or other derivative agreements of any nature with respect to any Voting Securities; and (f) the Director (or any Successor Directors) will not be, and Xxxxxx will not consider the Director (or any Successor Directors) to be, stockholder designees or stockholder representatives of Xxxxxx.

6.Term. Except as otherwise set forth herein, the term of this Agreement (the “Term”) shall commence on the Effective Date and shall continue until the date (the “Expiration Date”) that is the earlier of (a) January 1, 2023 and (b) the date that is thirty (30) days prior to the

7

deadline under the Bylaws for director nominations and shareholder proposals for the 2023 Annual Meeting; provided, that, if the Xxxxxx Consultant shall be appointed to the Board prior to the Expiration Date, then the Expiration Date shall be extended to the date that is one day after the date of the 2023 Annual Meeting; provided, however, that (i) Xxxxxx may earlier terminate this Agreement if the Company commits a material breach of its obligations under this Agreement that (if capable of being cured) is not cured within fifteen (15) days after receipt by the Company from Xxxxxx specifying the material breach, or, if impossible to cure within fifteen (15) days, that the Company has not taken any substantive action to cure within such fifteen (15)-day period, (ii) the Company may earlier terminate this Agreement if Xxxxxx commits a material breach of this Agreement that (if capable of being cured) is not cured within fifteen (15) days after receipt by Xxxxxx from the Company specifying the material breach, or, if impossible to cure within fifteen (15) days, that Xxxxxx has not taken any substantive action to cure within such fifteen (15)-day period and (iii) either the Company or Xxxxxx may earlier terminate this Agreement upon the consummation of a Change of Control (as defined below); provided further that no expiration or termination of this Agreement will relieve any Party hereto from any liability for a breach of this Agreement prior to such expiration or termination. Notwithstanding the foregoing, Section 10 through Section 15 shall survive the termination or expiration of this Agreement. A “Change of Control” shall be deemed to have taken place if (x) any person is or becomes a beneficial owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the equity interests and voting power of the Company’s then outstanding equity securities, (y) as a result of a merger or stock-for-stock transaction the Company’s stockholders retain less than fifty percent (50%) of the equity interests and voting power of the surviving entity’s then-outstanding equity securities or (z) the Company sells all or substantially all of its assets.

7.Fiduciary Duties; Rights of the Director.

(a)Fiduciary Duties. Notwithstanding anything in this Agreement to the contrary, nothing contained herein shall require any director to violate his or her fiduciary duties.

(b)Director Benefits. The Company agrees that the Director shall receive (i) the same benefits of director and officer insurance, and any indemnity and exculpation arrangements available generally to the directors of the Board and (ii) such other benefits on the same basis as all other non-management directors on the Board, including, unless otherwise requested by the Director, having the Company (or legal counsel) prepare and file with the SEC, at the Company’s expense, any Form 3, Form 4 and Form 5 under Section 16 of the Exchange Act that are required to be filed by each director of the Company.

8.Expenses. No later than five (5) business days following the execution of this Agreement, the Company shall reimburse Xxxxxx for its reasonable and documented out-of-pocket fees and expenses (including attorney’s fees and other legal expenses and expenses related to the engagement of other advisors and consultants) incurred by Xxxxxx prior to the Effective Date in connection with its engagement with the Company and the negotiation and execution of this Agreement and the transactions contemplated hereby not to exceed the aggregate amount previously agreed to by the Parties.

9.Counterparts. This Agreement may be executed in two or more counterparts, each of which will be considered one and the same agreement and will become effective when counterparts have been signed by each of the Parties and delivered to the other Party (including by means of electronic delivery or facsimile).

10.Specific Performance. Each Party acknowledges and agrees that irreparable injury to the other Party would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached and that

8

money damages may not be an adequate remedy for such a breach. It is accordingly agreed that each Party may be entitled to specific enforcement of, and injunctive relief to prevent any violation of, the terms hereof. Each Party agrees to waive any bonding requirement under any applicable law in the case any other Party seeks to enforce the terms by way of equitable relief.

11.APPLICABLE LAW AND JURISDICTION. THIS COOPERATION AGREEMENT WILL BE GOVERNED BY, AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE WITHOUT REFERENCE TO CONFLICTS OF LAWS PRINCIPLES. EACH OF THE PARTIES IRREVOCABLY AGREES THAT ANY LEGAL ACTION OR PROCEEDING TO ENFORCE THIS COOPERATION AGREEMENT WILL BE BROUGHT EXCLUSIVELY IN (A) THE DELAWARE COURT OF CHANCERY IN AND FOR NEW CASTLE COUNTY, (B) IN THE EVENT (BUT ONLY IN THE EVENT THAT SUCH COURT DOES NOT HAVE SUBJECT MATTER JURISDICTION OVER SUCH ACTION), THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE OR (C) IN THE EVENT (BUT ONLY IN THE EVENT) SUCH COURTS IDENTIFIED IN CLAUSES (A) AND (B) DO NOT HAVE SUBJECT MATTER JURISDICTION OVER SUCH ACTION, ANY OTHER DELAWARE STATE COURT (COLLECTIVELY, THE “CHOSEN COURTS”). EACH OF THE PARTIES IRREVOCABLY WAIVES THE RIGHT TO TRIAL BY JURY IN ANY SUCH ACTION OR PROCEEDING. EACH OF THE PARTIES HEREBY IRREVOCABLY SUBMITS TO THE PERSONAL JURISDICTION OF THE CHOSEN COURTS, AND IRREVOCABLY WAIVES ANY ARGUMENT THAT THE CHOSEN COURTS ARE AN INCONVENIENT OR IMPROPER FORUM. EACH PARTY CONSENTS TO SERVICE OF PROCESS BY A REPUTABLE OVERNIGHT DELIVERY SERVICE, SIGNATURE REQUESTED, TO THE ADDRESS OF SUCH PARTY’S PRINCIPAL PLACE OF BUSINESS OR AS OTHERWISE PROVIDED BY APPLICABLE LAW.

12.Notice. All notices, consents, requests, instructions, approvals and other communications provided for in this Agreement and all legal process in regard hereto shall be in writing and shall be deemed validly given, made or served, (a) if given by email, when such email is transmitted to the email address set forth below (so long as the sender of such email does not receive an automatic message indicating that the recipient did not receive such email) or (b) if given by any other means, when actually received during normal business hours at the address specified in this Section:

If to the Company:

ViewRay, Inc.
0000 00xx Xxxxxx, Xxxxx 0000
Xxxxxx, XX 00000
Attention: Xxxxxx XxXxxxxxx
Email: xxxxxxxxxx@xxxxxxx.xxx

With a copy to (which shall not constitute notice):

Cravath, Swaine & Xxxxx LLP
000 Xxxxxx Xxxxxx
Xxx Xxxx, XX 00000
Attention:    Xxxx Xxx Xxx
        Xxxxxx X. Xxxx
Email:        xxxx@xxxxxxx.xxx
        xxxxx@xxxxxxx.xxx

9

If to Xxxxxx:

Xxxxxx Executive Capital LP
c/o Cadwalader, Xxxxxxxxxx & Xxxx LLP
000 Xxxxxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Attention:    General Counsel
Email:        Xxxxx@XxxxxxXxxxxxxxx.xxx

With a copy to (which shall not constitute notice):

Cadwalader, Xxxxxxxxxx & Xxxx LLP
000 Xxxxxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Attention:    Xxxxxxx Xxxxx
        Xxxxxx XxXxxxxxx
        Xxxxxx Xxxxxxxxx
Email:        xxxxxxx.xxxxx@xxx.xxx
        xxxxxx.xxxxxxxxx@xxx.xxx
        xxxxxx.xxxxxxxxx@xxx.xxx

13.Entire Agreement; Amendment. This Agreement, including exhibits and schedules attached to this Agreement, contains the entire understanding of the Parties with respect to the subject matter hereof. This Agreement may be amended only by an agreement in writing executed by the Parties, and no waiver of compliance with any provision or condition of this Agreement and no consent provided for in this Agreement shall be effective unless evidenced by a written instrument executed by the Party against whom such waiver or consent is to be effective. No failure or delay by a Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any right, power or privilege hereunder.

14.Severability. If at any time subsequent to the date of this Agreement, any provision of this Agreement shall be held by any court of competent jurisdiction to be illegal, void or unenforceable, such provision shall be of no force and effect, but the illegality or unenforceability of such provision shall have no effect upon the legality or enforceability of any other provision of this Agreement.

15.No Third Party Beneficiaries; Assignment. This Agreement is solely for the benefit of the Parties and is not binding upon or enforceable by any other persons. No Party may assign its rights or delegate its obligations under this Agreement, whether by operation of law or otherwise, and any assignment in contravention hereof shall be null and void. Nothing in this Agreement, whether express or implied, is intended to or shall confer any rights, benefits or remedies under or by reason of this Agreement on any persons other than the Parties, nor is anything in this Agreement intended to relieve or discharge the obligation or liability of any third persons to any Party.

[Signature Page Follows]

10

If the terms of this Agreement are in accordance with your understanding, please sign below and this Agreement will constitute a binding agreement among us.

VIEWRAY, INC.


By:    
    Name:    Xxxxx X. Xxxxx
    Title:    Chief Executive Officer

[Signature Page to Cooperation Agreement]

Acknowledged and agreed to as of the date first written above:

XXXXXX EXECUTIVE CAPITAL LP,
on behalf of itself, its affiliates and its affiliated funds

By:    HEC Management GP LLC, its General Partner


By:    
    Name:    Xxxxxxx Xxxxxxxxxx
    Title:    Managing Member

[Signature Page to Cooperation Agreement]

EXHIBIT A

Press Release

ViewRay Enters into Cooperation Agreement with Xxxxxx Executive Capital

CLEVELAND, March 9, 2022-ViewRay, Inc. (NASDAQ: VRAY) today announced that it has reached an agreement with Xxxxxx Executive Capital LP (“HEC”) to appoint Xxxxx Xxxxxxxx to the ViewRay Board of Directors (the “Board”) as an independent director, effective as of March 8, 2022.

Xx. Xxxxxxxx brings significant financial and operational experience to the Board and has worked with numerous companies in executing value-generative transformation and advancing profitable innovation.

In addition, ViewRay has retained Xxx Xxxxxxx, a Senior Investment Analyst and representative of HEC, as a consultant to work with the Company to enhance shareholder returns. The Company has agreed to consider Xx. Xxxxxxx as a candidate for election to the Board at the 2023 annual stockholder meeting.

“ViewRay prides itself on its commitment to strong corporate governance and shareholder engagement. We look forward to welcoming Xx. Xxxxxxxx to our Board and working with Xx. Xxxxxxx,” said Xxxxx Xxxxx, President, Chief Executive Officer and Director of ViewRay. “This is an important time for ViewRay, and we are eager to benefit from their perspectives and valuable insights as we continue leveraging our clinical, innovation and commercial strength and positioning our company to capture significant opportunities.”

“We believe Xx. Xxxxxxxx will bring valuable perspectives to the Board that will help the Company on its mission,” said Xxxxxxx Xxxxxxxxxx, Co-Managing Partner of HEC. “We appreciate the opportunity to continue to work collaboratively with the Company and look forward to continuing our engagement with the Company to enhance shareholder value.”

In connection with this announcement, ViewRay has entered into a cooperation agreement with HEC, which currently owns approximately 8.8% of the Company’s outstanding common stock.

Pursuant to its agreement with ViewRay, HEC has agreed to customary standstill and voting commitments, among other provisions. The full agreement between HEC and ViewRay will be filed with the U.S. Securities and Exchange Commission on a Current Report on Form 8-K.

Separately, ViewRay also announced that Xx. Xxxxx Xxx has tendered his resignation from the ViewRay Board effective March 8, 2022. "On behalf of ViewRay, I wish to thank Xxxxx for his valuable contributions and partnership, and we wish him continued success,” said Xxx Xxxxx, Chairman of the Board of ViewRay.

The Board will continue to consist of 9 members, eight of whom are independent.

About Xxxxx Xxxxxxxx

Xxxxx X. Xxxxxxxx is a founder and has served as the Co-Managing Partner of aPriori Capital Partners since 2014. Prior to forming aPriori Capital, Xx. Xxxxxxxx worked at Credit Suisse from 2000 to 2014 where she served as Managing Director in the Asset Management Division and Co-Head of DLJ Merchant Banking. Xx. Xxxxxxxx currently serves on the board of directors of Altice USA, Inc. and Xxxxx Xxxxxxxx BDC. She served on the board of directors of Versum Materials, Inc. from 2016 through 2019 and has significant other board experience with private and public companies. Xx. Xxxxxxxx also serves on the Cornell University Board of Trustees (Investment and Finance Committees), the California Institute of Technology Investment Committee and the Board of Directors of the US Olympic & Paralympic Foundation (Finance Committee). Xx. Xxxxxxxx received a bachelor of science in chemical engineering from Cornell University and a masters of business administration from Harvard Business School.

About ViewRay

ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

About Xxxxxx Executive Capital

Xxxxxx Executive Capital ("HEC") is a New York City-based value-oriented investor focused on engaging with US small and mid-cap public companies with identified and actionable opportunities to create outsized returns. Seasoned operating executives Xxxxxxx Xxxxxxxxxx and Xxxxxxx Xxxxxxxx lead an experienced investment team to help companies catalyze value and drive returns. A group of 30+ current and former public company CEOs are LPs in the fund and support all aspects of the investment model, including idea generation, investment due diligence, and execution. For more information about HEC, please visit xxx.xxxxxxxxxxxxxxx.xxx.

Advisors

Cravath, Swaine & Xxxxx LLP is serving as legal advisor to ViewRay. Cadwalader, Xxxxxxxxxx & Xxxx LLP is serving as legal advisor to HEC.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, ViewRay's financial guidance for the full year 2022, anticipated future orders, anticipated future operating and financial performance, treatment results, therapy adoption, innovation and the performance of the MRIdian systems. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize the MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, the timing of delivery of ViewRay's products, the timing, length, and severity of the COVID-19 pandemic, including its impacts across our businesses on demand, our operations and global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and its Quarterly Reports on Form 10-Q, as updated periodically with the Company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Media Enquiries:

Xxxxxxxx Xxxxx

Director, Marketing Communications

ViewRay, Inc.

xxxxx@xxxxxxx.xxx

Investor Relations:

Xxxx Xxxxxxxx

Investor Relations

ViewRay, Inc.

xxxxxxxxx@xxxxxxx.xxx

SCHEDULE A

HEC Management GP LLC

HEC Master Fund LP